Cargando…

Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline

Objectives: Resistance-associated variants (RAVs) in Rv0678, a regulator of the MmpS5-MmpL5 efflux pump, have been shown to lead to increased MICs of bedaquiline (2- to 8- fold) and clofazimine (2- to 4-fold). The prevalence of these Rv0678 RAVs in clinical isolates and their impact on treatment out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villellas, Cristina, Coeck, Nele, Meehan, Conor J., Lounis, Nacer, de Jong, Bouke, Rigouts, Leen, Andries, Koen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400087/ https://www.ncbi.nlm.nih.gov/pubmed/28031270 http://dx.doi.org/10.1093/jac/dkw502

Ejemplares similares

Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
por: Snobre, J., et al.
Publicado: (2023)

Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline
por: Kaniga, K., et al.
Publicado: (2022)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Circularization of rv0678 for Genotypic Bedaquiline Resistance Testing of Mycobacterium tuberculosis
por: Limberis, Jason D., et al.
Publicado: (2023)

Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan
por: Saeed, Dania Khalid, et al.
Publicado: (2022)

Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
por: Almeida, Deepak, et al.
Publicado: (2021)

Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2021)

Prolonged use of bedaquiline in the treatment for MDR-TB in a child
por: Gubkina, Marina F., et al.
Publicado: (2021)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Genetic variability of Mycobacterium tuberculosis complex in patients with no known risk factors for MDR-TB in the North-eastern part of Lima, Peru
por: Barletta, Francesca, et al.
Publicado: (2013)

Specific gyrA gene mutations predict poor treatment outcome in MDR-TB
por: Rigouts, L., et al.
Publicado: (2016)

Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan
por: Ghodousi, Arash, et al.
Publicado: (2019)

Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis
por: Sonnenkalb, Lindsay, et al.
Publicado: (2023)

Rv1453 is associated with clofazimine resistance in Mycobacterium tuberculosis
por: Zhang, Lei, et al.
Publicado: (2023)

Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians
por: Cesilia, Citra, et al.
Publicado: (2023)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
por: Shi, Jin, et al.
Publicado: (2023)

Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates
por: Kaniga, Koné, et al.
Publicado: (2022)

Bedaquiline for multidrug-resistant TB in paediatric patients
por: Moodliar, R., et al.
Publicado: (2021)

Clofazimine pharmacokinetics in patients with TB: dosing implications
por: Abdelwahab, Mahmoud Tareq, et al.
Publicado: (2020)

Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis
por: Coeck, Nele, et al.
Publicado: (2016)

Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis
por: Yao, Ge, et al.
Publicado: (2023)

Network analysis identifies Rv0324 and Rv0880 as regulators of bedaquiline tolerance in Mycobacterium tuberculosis
por: Peterson, Eliza J.R., et al.
Publicado: (2016)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
por: Codecasa, Luigi R., et al.
Publicado: (2017)

Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis
por: Ismail, N., et al.
Publicado: (2018)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study
por: Li, Rong, et al.
Publicado: (2023)

Comparing mRNA expression and protein abundance in MDR Mycobacterium tuberculosis: Novel protein candidates, Rv0443, Rv0379 and Rv0147 as TB potential diagnostic or therapeutic targets
por: Hadizadeh Tasbiti, Alireza, et al.
Publicado: (2021)

The Transcription Factor Rv1453 Regulates the Expression of qor and Confers Resistant to Clofazimine in Mycobacterium tuberculosis
por: Li, Yuanyuan, et al.
Publicado: (2021)

‘Z(S)-MDR-TB' versus ‘Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility
por: Zhang, Ying, et al.
Publicado: (2012)

Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
por: Faraj, Alan, et al.
Publicado: (2020)

Development of Bedaquiline-Loaded SNEDDS Using Quality by Design (QbD) Approach to Improve Biopharmaceutical Attributes for the Management of Multidrug-Resistant Tuberculosis (MDR-TB)
por: Jahan, Rao Nargis, et al.
Publicado: (2023)

Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB
por: Kambili, C., et al.
Publicado: (2022)

MDR TB Transmission, Singapore
por: Chee, Cynthia B.E., et al.
Publicado: (2013)

First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda
por: Kabahita, Jupiter Marina, et al.
Publicado: (2022)

MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era
por: Beckert, Patrick, et al.
Publicado: (2020)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis
por: Nimmo, Camus, et al.
Publicado: (2020)

Dually Acting Nonclassical 1,4-Dihydropyridines Promote the Anti-Tuberculosis (Tb) Activities of Clofazimine
por: Lentz, Fabian, et al.
Publicado: (2019)

Mycobacterium tuberculosis complex lineage 5 exhibits high levels of within-lineage genomic diversity and differing gene content compared to the type strain H37Rv
por: Sanoussi, C. N'Dira, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kku6bpnh9tkriok11201m7699s